FibroBiologics’ (FBLG) “Buy” Rating Reiterated at D. Boral Capital

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They presently have a $16.00 price objective on the stock.

Other equities analysts have also recently issued research reports about the stock. Rodman & Renshaw initiated coverage on shares of FibroBiologics in a research note on Thursday, December 12th. They issued a “buy” rating and a $12.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of FibroBiologics in a research note on Thursday, February 13th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, FibroBiologics presently has an average rating of “Buy” and a consensus price target of $13.00.

FibroBiologics Price Performance

Shares of NASDAQ:FBLG traded up $0.05 during trading on Thursday, hitting $1.19. The company’s stock had a trading volume of 103,993 shares, compared to its average volume of 369,335. The company has a 50-day moving average of $1.75 and a 200-day moving average of $2.28. FibroBiologics has a 12 month low of $0.98 and a 12 month high of $14.70.

Institutional Investors Weigh In On FibroBiologics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Intech Investment Management LLC purchased a new stake in FibroBiologics during the 4th quarter valued at approximately $25,000. Virtu Financial LLC purchased a new stake in FibroBiologics during the 4th quarter valued at approximately $30,000. The Manufacturers Life Insurance Company purchased a new stake in FibroBiologics during the 3rd quarter valued at approximately $32,000. Jane Street Group LLC purchased a new stake in FibroBiologics during the 3rd quarter valued at approximately $37,000. Finally, Raymond James Financial Inc. purchased a new stake in FibroBiologics during the 4th quarter valued at approximately $37,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.